Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma

Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received FDA approval for the treatment of transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM). The present PEGASUS study compared progression‐free survival (PFS) in patients treated with D‐Rd in the M...

Descripción completa

Detalles Bibliográficos
Autores principales: Durie, Brian G. M., Kumar, Shaji K., Usmani, Saad Z., Nonyane, Bareng A. S., Ammann, Eric M., Lam, Annette, Kobos, Rachel, Maiese, Eric M., Facon, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754114/
https://www.ncbi.nlm.nih.gov/pubmed/32804408
http://dx.doi.org/10.1002/ajh.25963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754114/
https://www.ncbi.nlm.nih.gov/pubmed/32804408
http://dx.doi.org/10.1002/ajh.25963

Ejemplares similares